Climb Bio licenses CLYM116, an anti-APRIL antibody, expanding its immune-mediated disease pipeline, with preclinical data expected in 2025. Climb Bio, Inc. has announced an exclusive licensing ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

HERCULES, Calif. - Bio-Rad Laboratories (NYSE:BIO), Inc. (NYSE: BIO and BIO.B), a $8.49 billion market cap company known for its life science research and clinical diagnostics products, has announced ...

HERCULES, Calif., July 31, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the ...

Move over, A: B is taking the lead now, with Be Biopharma closing out a $130 million financing round backed by several industry leaders that will fuel its engineered B cells platform. The biotech aims ...

Shares of Nuvation Bio (NUVB) climbed ~48% on Wednesday after B. Riley Securities launched its coverage with a Buy recommendation and a $12 per share target, citing early signs of a successful ...

ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and ...

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the ...

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

HERCULES, Calif., October 29, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for ...